Design and methods of a postmarketing pharmacoepidemiology study assessing long-term safety of Prolia® (denosumab) for the treatment of postmenopausal osteoporosis‡

Por Xue, Fei, Ma, Haijun, Stehman-Breen, Catherine, Haller, Christine, Katz, Leonid, Wagman, Rachel B, Critchlow, Cathy W, Denosumab Global Safety Assessment Team
Publicado no Pharmacoepidemiol Drug Saf (2013)

Discontinuation of Denosumab and Associated Fracture Incidence: Analysis From the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial

Por Brown, Jacques P, Roux, Christian, Törring, Ove, Ho, Pei-Ran, Beck Jensen, Jens-Erik, Gilchrist, Nigel, Recknor, Christopher, Austin, Matt, Wang, Andrea, Grauer, Andreas, Wagman, Rachel B
Publicado em 2013

Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study

Por Adachi, Jonathan D., Bone, Henry G., Daizadeh, Nadia S., Dakin, Paula, Papapoulos, Socrates, Hadji, Peyman, Recknor, Chris, Bolognese, Michael A., Wang, Andrea, Lin, Celia J. F., Wagman, Rachel B., Ferrari, Serge
Publicado no BMC Musculoskelet Disord (2017)

The Effect of Three or Six Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the FREEDOM Extension

Por Bone, Henry G., Chapurlat, Roland, Brandi, Maria-Luisa, Brown, Jacques P., Czerwiński, Edward, Krieg, Marc-Antoine, Mellström, Dan, Radominski, Sebastião C., Reginster, Jean-Yves, Resch, Heinrich, Ivorra, Jose A. Román, Roux, Christian, Vittinghoff, Eric, Daizadeh, Nadia S., Wang, Andrea, Bradley, Michelle N., Franchimont, Nathalie, Geller, Michelle L., Wagman, Rachel B., Cummings, Steven R., Papapoulos, Socrates
Publicado em 2013